On the chart you can see the default numbers in dynamics for Denali Therapeutics Inc. (DNLI). Companys revenue shows the average of 108.795 M which is 1.468 % gowth. The average gross profit for the whole period is 60.421 M which is 0.250 %. The average gross profit ratio is -0.235 %. The net income growth for the company last year performance is -0.555 % which equals -1.259 % % on average for the whole company history.,
Diving into the fiscal trajectory of Denali Therapeutics Inc., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of -0.210. In the realm of current assets, DNLI clocks in at 1064.137 in the reporting currency. A significant portion of these assets, precisely 1034.511, is held in cash and short-term investments. This segment shows a change of -0.226% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 1.6, if any, in the reporting currency. This indicates a difference of 6.667% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 44.981 in the reporting currency. This figure signifies a year_over_year change of -0.134%. Shareholder value, as depicted by the total shareholder equity, is valued at 1030.954 in the reporting currency. The year over year change in this aspect is -0.011%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 2.7, with an inventory valuation of 0, and goodwill valued at 0, if any. The total intangible assets, if present, are valued at 0.
The financial landscape of Denali Therapeutics Inc. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of -0.413. The company recently extended its share capital by issuing 17.82, marking a difference of 1.483 compared to the previous year. Interestingly, a portion of the company's stock, specifically 0, was bought back by the company itself. This action resulted in a change of 0.000 from the previous year. Meanwhile, the company's account payables are currently standing at 2.43 in the reporting currency. The company's investing activities resulted in net cash usage, amounting to 249308000.000 in the reporting currency. This is a shift of -2.763 from the previous year. In the same period, the company recorded 16.73, 0, and 0, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated 0 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as 17.82, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.
Denali Therapeutics Inc.'s revenue saw a change of 2.047% compared with the previous period. The gross profit of DNLI is reported to be 313.81. The company's operating expenses are 510.5, showing a change of 13.646% from the last year. The expenses for depreciation and amortization are 16.73, which is a 0.611% change from the last accounting period. Operating expenses are reported to be 510.5, which shows a 13.646% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a 0.423% year-over-year growth. The operating income is -196.7, which shows a -0.423% change when compared to the previous year. The change in the net income is -0.555%. The net income for the last year was -145.22.
